IMBALANCE OF PLASMINOGEN ACTIVATORS AND THEIR INHIBITORS IN HUMAN COLORECTAL NEOPLASIA - IMPLICATION OF UROKINASE IN COLORECTAL CARCINOGENESIS

被引:79
作者
SIER, CFM [1 ]
VERSPAGET, HW [1 ]
GRIFFIOEN, G [1 ]
VERHEIJEN, JH [1 ]
QUAX, PHA [1 ]
DOOIJEWAARD, G [1 ]
DEBRUIN, PAF [1 ]
LAMERS, CBHW [1 ]
机构
[1] LEIDEN UNIV HOSP,DEPT GASTROENTEROL & HEPATOL,BLDG 1,C4-P12,RIJNSBURGERWEG 10,2333 AA LEIDEN,NETHERLANDS
关键词
D O I
10.1016/0016-5085(91)90387-Z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Neoplastic growth and metastatic spread of adenocarcinomas is characterized by a marked increase of urokinase-type plasminogen activator (u-PA) and a decrease of tissue-type plasminogen activator (t-PA). In this study, the authors determined the activity and antigen levels of u-PA and t-PA, and their inhibitors, plasminogen-activator inhibitors types 1 and 2 (PAI-1 and PAI-2), in normal mucosa, adenomatous polyps, and adenocarcinomas of the human colon. The decrease in t-PA activity in the neoplastic tissues, determined enzymatically and zymographically, was significantly correlated with an increase in PAI-1 and PAI-2, in particular in carcinomas. In spite of significantly higher inhibitor levels in the neoplastic tissues, u-PA was found to be increased as well, both in antigen level and in activity. The authors conclude that PAI-1 and PAI-2 are significantly increased in neoplastic tissue of the human colon and contribute considerably to the decrease of t-PA activity in carcinomas. However, the malignancy-associated increase in u-PA seems not to be affected by the plasminogen activator inhibitors. Thus, it appears that there is an imbalance between plasminogen activators and their inhibitors in colonic neoplasia in favor of u-PA, which may contribute to plasmin-mediated growth, invasiveness, and metastasis. This feature was also noticed in adenomatous polyps, supporting the malignant potency of adenomas. © 1991.
引用
收藏
页码:1522 / 1528
页数:7
相关论文
共 49 条
[1]  
BAKER MS, 1990, CANCER RES, V50, P4676
[2]  
BEART RW, 1978, SURG GYNECOL OBSTET, V146, P257
[3]   QUANTITATION OF UROKINASE ANTIGEN IN PLASMA AND CULTURE MEDIA BY USE OF AN ELISA [J].
BINNEMA, DJ ;
VANIERSEL, JJL ;
DOOIJEWAARD, G .
THROMBOSIS RESEARCH, 1986, 43 (05) :569-577
[4]   UROKINASE-TYPE PLASMINOGEN-ACTIVATOR - PROENZYME, RECEPTOR, AND INHIBITORS [J].
BLASI, F ;
VASSALLI, JD ;
DANO, K .
JOURNAL OF CELL BIOLOGY, 1987, 104 (04) :801-804
[5]  
BOYD D, 1988, CANCER RES, V48, P3112
[6]  
BOYD D, 1989, CANCER RES, V49, P816
[7]  
CORASANTI JG, 1980, J NATL CANCER I, V65, P345
[8]   ACCESSIBILITY OF RECEPTOR-BOUND UROKINASE TO TYPE-1 PLASMINOGEN-ACTIVATOR INHIBITOR [J].
CUBELLIS, MV ;
ANDREASEN, P ;
RAGNO, P ;
MAYER, M ;
DANO, K ;
BLASI, F .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1989, 86 (13) :4828-4832
[9]   PLASMINOGEN ACTIVATORS, TISSUE DEGRADATION, AND CANCER [J].
DANO, K ;
ANDREASEN, PA ;
GRONDAHLHANSEN, J ;
KRISTENSEN, P ;
NIELSEN, LS ;
SKRIVER, L .
ADVANCES IN CANCER RESEARCH, 1985, 44 :139-266
[10]  
De Bruin PA, 1987, FIBRINOLYSIS, V1, P57